Cathie Wood Enlivex Therapeutics Ltd. Transaction History

Ark Investment Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 11, 2022	SELL	$3.81 - $8.64 $393,733 - $892,874	-103,342 Reduced 23.79%	331,001 $1.66 Million
Q1 2022 Apr 19, 2022	BUY	$4.92 - $6.66 $418,372 - $566,333	85,035 Added 24.34%	434,343 $2.43 Million
Q4 2021 Jan 28, 2022	SELL	$5.81 - $9.73 $630,321 - $1.06 Million	-108,489 Reduced 23.7%	349,308 $2.18 Million
Q3 2021 Nov 12, 2021	SELL	$7.43 - $13.86 $423,584 - $790,158	-57,010 Reduced 11.07%	457,797 $4.52 Million
Q2 2021 Aug 05, 2021	BUY	$8.61 - $12.1 $330,563 - $464,555	38,393 Added 8.06%	514,807 $4.58 Million
Q1 2021 May 13, 2021	BUY	$9.26 - $24.0 $4.41 Million - $11.4 Million	476,414 New	476,414 $5.28 Million
Q1 2020 May 14, 2020	SELL	$3.77 - $9.91 $145,280 - $381,891	-38,536 Closed	0 $0
Q4 2019 Jan 31, 2020	BUY	$6.61 - $27.48 $254,722 - $1.06 Million	38,536 New	38,536 $323,000

2.58M

20.8K

Ticker ENLV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,403,200
Market Cap $23M
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...

Get notified when there are updates to the investment portfolio of Ark Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Ark Investment Management LLC and Cathie Wood with notifications on news.